When it comes to developmental drugs, there's a lot of rumors and speculation thrown around about a drug's ultimate success or failure in clinical trials. When the time comes for that hard data, share prices are bound to soar or plummet in a big way. That's what happened today with BioMarin (Nasdaq: BMRN ) , which published phase 3 data around its drug treating an ultra-rare disorder called Morquio A syndrome. Follow along in the video as Brenton Flynn and Max Macaluso discuss today's news and a couple more companies in a similar situation to BioMarin.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.